Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma
Open Access
- 18 May 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (13), 2403-2416
- https://doi.org/10.1158/0008-5472.can-21-2352
Abstract
Altered metabolism helps sustain cancer cell proliferation and survival. Most cancers, including prostate cancers, express the M2 splice isoform of pyruvate kinase (PKM2), which can support anabolic metabolism to support cell proliferation. However, Pkm2 expression is dispensable for the formation and growth of many cancers in vivo. Expression of pyruvate kinase isoform M1 (Pkm1) is restricted to relatively few tissues and has been reported to promote growth of select tumors, but the role of PKM1 in cancer has been less studied than PKM2. To test how differential expression of pyruvate kinase isoforms affects cancer initiation and progression, we generated mice harboring a conditional allele of Pkm1 and crossed these mice, or those with a Pkm2 conditional allele, with a Pten loss-driven prostate cancer model. Pkm1 loss led to increased PKM2 expression and accelerated prostate cancer development, whereas Pkm2 deletion led to increased PKM1 expression and suppressed tumor progression. Metabolic profiling revealed altered nucleotide levels in tumors with high PKM1 expression, and failure of these tumors to progress was associated with DNA replication stress and senescence. Consistent with these data, a small molecule pyruvate kinase activator that mimics a high activity PKM1-like state suppressed progression of established prostate tumors. Analysis of human specimens showed PKM2 expression is retained in most human prostate cancers. Overall, this study uncovers a role for pyruvate kinase isoforms in prostate cancer initiation and progression, and argues that pharmacologic pyruvate kinase activation may be beneficial for treating prostate cancer.Other Versions
Funding Information
- NSF Graduate Research Fellowship (T32GM007287, W81XWH-15-1-0337)
- Catalyst Medical Research Investigator Training award (TR002542)
- NCI (R35CA197588)
- NIH (P30CA1405141, R35CA242379, R01CA168653, K08CA136983, P50CA090381)
This publication has 70 references indexed in Scilit:
- Synthetic lethal metabolic targeting of cellular senescence in cancer therapyNature, 2013
- Metformin Decreases Glucose Oxidation and Increases the Dependency of Prostate Cancer Cells on Reductive Glutamine MetabolismCancer Research, 2013
- Use of PB-Cre4 Mice for Mosaic Gene DeletionPLOS ONE, 2013
- M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growthProceedings of the National Academy of Sciences of the United States of America, 2012
- The functions and regulation of the PTEN tumour suppressorNature Reviews Molecular Cell Biology, 2012
- 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinaseBioorganic & Medicinal Chemistry Letters, 2011
- Mouse Models of Prostate CancerProstate Cancer, 2011
- The essence of senescence: Figure 1.Genes & Development, 2010
- Senescence in tumours: evidence from mice and humansNature Reviews Cancer, 2010
- Pten Dose Dictates Cancer Progression in the ProstatePLoS Biology, 2003